Geneos Wealth Management Inc. Increases Position in Astera Labs, Inc. $ALAB

Geneos Wealth Management Inc. raised its position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 1,382.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,033 shares of the company's stock after purchasing an additional 3,761 shares during the quarter. Geneos Wealth Management Inc.'s holdings in Astera Labs were worth $241,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Hoey Investments Inc. grew its stake in shares of Astera Labs by 4.2% in the first quarter. Hoey Investments Inc. now owns 5,000 shares of the company's stock worth $298,000 after acquiring an additional 200 shares in the last quarter. Sound Income Strategies LLC grew its stake in shares of Astera Labs by 34.7% in the first quarter. Sound Income Strategies LLC now owns 792 shares of the company's stock worth $47,000 after acquiring an additional 204 shares in the last quarter. Allworth Financial LP grew its stake in shares of Astera Labs by 20.4% in the first quarter. Allworth Financial LP now owns 1,394 shares of the company's stock worth $90,000 after acquiring an additional 236 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Astera Labs by 55.7% in the first quarter. GAMMA Investing LLC now owns 794 shares of the company's stock worth $47,000 after acquiring an additional 284 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC grew its stake in shares of Astera Labs by 1.1% in the first quarter. Wealthcare Advisory Partners LLC now owns 28,939 shares of the company's stock worth $1,727,000 after acquiring an additional 320 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company's stock.

Astera Labs Trading Up 0.8%

NASDAQ:ALAB opened at $231.29 on Tuesday. Astera Labs, Inc. has a 12-month low of $42.80 and a 12-month high of $237.82. The company's 50-day moving average is $157.95 and its two-hundred day moving average is $105.12. The firm has a market cap of $38.45 billion, a price-to-earnings ratio of 413.02, a price-to-earnings-growth ratio of 5.82 and a beta of 1.46.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The company had revenue of $191.93 million during the quarter, compared to the consensus estimate of $172.46 million. During the same quarter in the prior year, the company posted $0.13 EPS. The company's quarterly revenue was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, equities research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Astera Labs

In other news, General Counsel Philip Mazzara sold 10,000 shares of the business's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the completion of the sale, the general counsel owned 161,573 shares in the company, valued at approximately $30,488,825.10. The trade was a 5.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jitendra Mohan sold 91,441 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $183.51, for a total value of $16,780,337.91. Following the sale, the chief executive officer owned 2,170,877 shares of the company's stock, valued at $398,377,638.27. The trade was a 4.04% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,725,979 shares of company stock worth $254,102,940. Company insiders own 12.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ALAB shares. Needham & Company LLC boosted their price target on shares of Astera Labs from $100.00 to $170.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Evercore ISI lifted their price objective on shares of Astera Labs from $104.00 to $215.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. Jefferies Financial Group lifted their price objective on shares of Astera Labs from $95.00 to $130.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Wall Street Zen raised shares of Astera Labs from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Finally, William Blair assumed coverage on shares of Astera Labs in a research report on Thursday, May 22nd. They set an "outperform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $142.00.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.